“…In this design, it is impossible to separate out the effects of activation of the DREADD from any unexpected effects of CNO, which could be the enhancement or blockade of the expected result of DREADD activation. In terms of dosing, a wide range of doses (0.2–10 mg/kg) is regularly used in DREADD experiments (Alexander et al, 2009; Ferguson et al, 2011, 2013; Ray et al, 2011; Agulhon et al, 2013; Anderson et al, 2013; Farrell et al, 2013; Michaelides et al, 2013; Wang et al, 2013; Boender et al, 2014; Bull et al, 2014; Dell’Anno et al, 2014; Kätzel et al, 2014; Robinson et al, 2014; Zhu et al, 2014; Chang et al, 2015; Gompf et al, 2015; Mizoguchi et al, 2015; Pienaar et al, 2015; Scofield et al, 2015; Yau and McNally, 2015; Grace et al, 2016; Ma et al, 2016; Marchant et al, 2016; Qiu et al, 2016; Sengupta et al, 2016; Wicker and Forcelli, 2016), and there is seldom any explanation given as to how the dose that was used was decided upon. Using the lowest effectual dose in the assay to be performed, that which in the non-DREADD-expressing animals is experimentally silent, would seem the most straightforward way to minimize any off-target effects of CNO.…”